3//SEC Filing
venBio Global Strategic Fund II L.P. 3
Accession 0000905148-20-000868
CIK 0001651431other
Filed
Aug 5, 8:00 PM ET
Accepted
Aug 6, 9:03 PM ET
Size
13.5 KB
Accession
0000905148-20-000868
Insider Transaction Report
Form 3
venBio Global Strategic Fund II L.P.
10% Owner
Holdings
Series A Preferred Stock
→ Common Stock (1,671,771 underlying)Series B Preferred Stock
→ Common Stock (1,314,165 underlying)Series C Preferred Stock
→ Common Stock (487,438 underlying)
venBio Global Strategic GP II, L.P.
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (1,314,165 underlying)Series A Preferred Stock
→ Common Stock (1,671,771 underlying)Series C Preferred Stock
→ Common Stock (487,438 underlying)
venBio Global Strategic GP II, Ltd.
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (1,314,165 underlying)Series A Preferred Stock
→ Common Stock (1,671,771 underlying)Series C Preferred Stock
→ Common Stock (487,438 underlying)
GOODMAN COREY S
10% Owner
Holdings
Series A Preferred Stock
→ Common Stock (1,671,771 underlying)Series C Preferred Stock
→ Common Stock (487,438 underlying)Series B Preferred Stock
→ Common Stock (1,314,165 underlying)
Adelman Robert J
10% Owner
Holdings
Series A Preferred Stock
→ Common Stock (1,671,771 underlying)Series B Preferred Stock
→ Common Stock (1,314,165 underlying)Series C Preferred Stock
→ Common Stock (487,438 underlying)
Footnotes (3)
- [F1]The Series A Preferred Stock and Series C Preferred Stock is convertible into Common Stock at a rate of 1:7.4771 into the number of shares of Common Stock as shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date.
- [F2]The Series B Preferred Stock is convertible into Common Stock at a rate of 1.12256:7.4771 into the number of shares of Common Stock as shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date.
- [F3]The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.
Documents
Issuer
Checkmate Pharmaceuticals, Inc.
CIK 0001651431
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001634632
Filing Metadata
- Form type
- 3
- Filed
- Aug 5, 8:00 PM ET
- Accepted
- Aug 6, 9:03 PM ET
- Size
- 13.5 KB